Yes. Sofosbuvir’s absorption is not significantly affected by food, so it may be taken with or without a meal. Consistency in timing helps maintain steady drug levels.
Take the missed tablet as soon as you remember on the same day. Do not double-dose the following day; simply continue with your regular once-daily schedule.
While Sofosbuvir does not interact directly with alcohol, patients with chronic hepatitis C should limit alcohol intake to avoid additional liver injury. Discuss your alcohol consumption with your clinician.
Cure is defined by a sustained virologic response (SVR) 12 weeks after completing the prescribed treatment course, which is usually 12 weeks for most regimens.
For patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min), standard dosing is appropriate. Severe renal impairment requires specialist evaluation and possible dose modification.
Symptoms may include dizziness, fainting, fatigue, or a markedly slow pulse (< 50 beats per minute). Immediate medical assessment is essential.
Most common vitamins and minerals do not affect Sofosbuvir. However, herbal products that induce P-gp (e.g., St. John’s wort) could lower drug exposure; inform your provider of any supplements you use.
Combining Sofosbuvir with agents that target different steps of the HCV life cycle (e.g., NS5A inhibitors) enhances viral clearance, broadens genotype coverage, and reduces the risk of resistance.
Eligibility for National Health Service (NHS) funding depends on clinical criteria such as disease stage, genotype, and prior treatment history. A specialist will assess suitability based on current NICE guidelines.
Keep the tablets in their original container at room temperature, away from excessive heat, humidity, or direct sunlight. Carry them in hand luggage to avoid temperature extremes in checked baggage.
Sofosbuvir is an antiviral medication classified as a direct-acting agent against hepatitis C virus (HCV). It is supplied as a 400 mg oral pill and is approved for prescription use in the United Kingdom under the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is marketed under several brand names, most notably Sovaldi (Gilead Sciences). It belongs to the class of NS5B polymerase inhibitors and is used as a key component of combination regimens for chronic HCV infection.
Sofosbuvir targets the HCV NS5B RNA-dependent RNA polymerase, an enzyme essential for viral genome replication. After oral ingestion, the prodrug is converted in the liver to its active nucleoside triphosphate form. This active metabolite competes with natural nucleotides and becomes incorporated into the growing viral RNA chain, resulting in premature chain termination. By halting viral replication, Sofosbuvir reduces the viral load and allows the immune system to clear the infection. Onset of antiviral activity occurs within hours, with peak plasma concentrations reached about 0.5-2 hours after dosing; the drug’s half-life supports once-daily administration.
In the UK, Sofosbuvir is approved for the treatment of chronic hepatitis C infection in adults when used in combination with other antiviral agents. Approved regimens include:
The medication is indicated for patients with compensated liver disease (Child-Pugh class A) and for many with decompensated disease (class B) when combined appropriately. Treatment duration typically ranges from 12 to 24 weeks, depending on the regimen, genotype, and presence of cirrhosis.
These effects are usually mild and transient, often improving without intervention.
Sofosbuvir is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Co-administration with drugs that strongly inhibit or induce these transporters can alter Sofosbuvir exposure.
Major interactions
Amiodarone - risk of serious bradycardia; avoid concomitant use or ensure intensive cardiac monitoring.
Concomitant strong P-gp inducers (e.g., carbamazepine, phenytoin, rifampicin) - may reduce Sofosbuvir levels and compromise efficacy.
Moderate interactions
Antiretrovirals such as atazanavir/ritonavir or efavirenz can modestly affect drug concentrations; dose adjustments of the accompanying HCV agents may be required.
Patients should provide a full medication list, including over-the-counter products and herbal supplements, to their prescriber.
This article provides educational information about Sofosbuvir and is not a substitute for professional medical advice. Treatment decisions, including the use of Sofosbuvir for any indication, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
